Rising Pharmaceuticals Inc., generic finished dosage form subsidiary of Aceto Corporation, has announced the launch of flucytosine capsules of 250 mg and 500 mg strengths and 500 mg strength of chloroquine phosphate tablets.

Flucytosine capsules is the first approved generic version of Valeant Pharmaceuticals International's Ancobon capsules, and 500 mg strength of chloroquine phosphate tablets, an approved generic version of Sanofi Aventis US's Aralen tablets.

According to IMS Health data, US brand sales for Flucytosine, which is used in the treatment of serious infections, and Chloroquine Phosphate, which is used to treat and prevent malaria infections, were approximately $20 million collectively for the twelve months ended June, 2011.

Albert Eilender, Aceto's chairman and CEO, stated, “The Chloroquine Phosphate launch marks the first leveraging of a product by Rising that was brought to them directly as a result of Aceto's worldwide sourcing capabilities. This illustrates the synergistic business opportunities we believe will become more plentiful as we move forward.”

Commenting on the launches, Ronald Gold, president and COO of Rising, stated, “We are pleased to have been the first company to launch a generic version of Valeant's Ancobon and look forward to additional product offerings in this fiscal year.”

Aceto Corporation, a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceuticals products, agricultural protection products and specialty chemicals.